Welcome to our dedicated page for Arrivent Biopharma SEC filings (Ticker: AVBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ArriVent BioPharma, Inc. (AVBP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ArriVent is a Nasdaq-listed, clinical-stage biopharmaceutical company, and its filings offer insight into the development of firmonertinib and its antibody-drug conjugate pipeline, as well as its capital structure and governance.
Through current reports on Form 8-K, ArriVent reports material events such as quarterly financial results, interim and final clinical data updates for firmonertinib in EGFR exon 20 insertion and PACC mutant non-small cell lung cancer (NSCLC), public offerings of common stock and pre-funded warrants, and collaboration agreements. These filings also confirm that ArriVent’s common stock trades on The Nasdaq Stock Market LLC under the symbol AVBP and identify the company as an emerging growth company.
Investors can use this page to review how ArriVent describes its pivotal Phase 3 trials like FURVENT and ALPACCA, its Phase 1b FURTHER study, and regulatory milestones such as FDA Breakthrough Therapy Designation and Orphan Drug Designation for firmonertinib. Filings may also discuss pipeline assets such as ARR-217 (MRG007), a CDH17-targeted ADC, and outline how equity offerings and cash resources are intended to support ongoing research and development.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on clinical trial status, financial condition, and corporate actions. Real-time updates from EDGAR, along with structured access to 8-Ks and other core filings, allow users to monitor changes in ArriVent’s development programs, financing activities, and governance without manually parsing every page.
ArriVent BioPharma’s General Counsel, James Paul Kastenmayer, received a stock option grant reported on a Form 4. He was awarded options covering 130,000 shares of common stock at an exercise price of $22.67 per share.
The option was granted on February 2, 2026. The underlying shares vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments after that date, conditioned on his continued service. Following this grant, he beneficially owns 130,000 stock options directly.
Hillhouse-affiliated investment entities reduced their stake in ArriVent BioPharma, Inc. A group of vehicles managed by Hillhouse Investment Management and HHLR Advisors reported selling 555,555 shares of ArriVent common stock on December 10, 2025 at $23.37 per share.
After this sale, the reporting group indirectly held 3,929,117 ArriVent shares through entities including HACF, L.P., VSUM VI Holdings Limited, VSUM VIII Holdings Limited and ARVT Holdings Limited. Hillhouse Investment Management, Ltd. and HHLR Advisors, Ltd. filed jointly as 10% owners and expressly disclaim beneficial ownership beyond their pecuniary interests.
The Vanguard Group reported beneficial ownership of 1,869,266 shares of ArriVent Biopharma Inc. common stock, representing 4.52% of the class as of 12/31/2025. Vanguard has no sole voting or dispositive power, with shared voting power over 242,661 shares and shared dispositive power over 1,869,266 shares.
Vanguard states that these securities are held in the ordinary course of business and not to change or influence control of ArriVent. Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds, with no single client holding more than 5%. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Arrivent Biopharma Inc. common stock. BlackRock reports beneficial ownership of 2,319,341 shares, representing 5.6% of Arrivent’s outstanding common shares as of the event date.
The filing states that BlackRock has sole power to vote 2,279,791 shares and sole power to dispose of all 2,319,341 shares, with no shared voting or dispositive power. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Arrivent Biopharma.
ArriVent BioPharma (AVBP) filed its Q3 2025 10-Q, reporting a net loss of $34,978 thousand for the quarter and $130,764 thousand year-to-date as it advances oncology programs led by firmonertinib. Operating expenses rose with research and development at $32,167 thousand in Q3 (driven by Phase 3 FURVENT and early-stage programs) and general and administrative at $6,149 thousand. Interest and investment income was $3,338 thousand.
Liquidity strengthened: cash and cash equivalents were $112,672 thousand and short-term investments were $187,594 thousand at September 30, 2025. The company states aggregate cash, cash equivalents and marketable securities of $305.4 million as of September 30, 2025 are sufficient to sustain planned operations through at least twelve months from the issuance date. Capital actions included $87.3 million net through an at-the-market program and $80.6 million net from a July underwritten offering. A $75.0 million term loan facility remains undrawn. Clinical updates highlight firmonertinib across multiple EGFR-mutant NSCLC settings, including a pivotal Phase 3 and a planned randomized Phase 3 study. Shares outstanding were 41,281,361 as of November 7, 2025.
ArriVent BioPharma, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025. On November 10, 2025, the company issued a press release with these quarterly results, which is attached as Exhibit 99.1.
The company specifies that the press release and the related disclosure are being furnished rather than filed under U.S. securities laws, meaning they are not subject to certain liability provisions and are not automatically incorporated into other SEC filings.
ArriVent BioPharma, Inc. filed a report describing a new corporate update related to its lung cancer drug development work. The company issued a press release announcing that it presented the final analysis of firmonertinib monotherapy data from its global phase 1b study in EGFR PACC mutant non-small cell lung cancer at the 2025 World Conference on Lung Cancer.
The press release is included as Exhibit 99.1 and most of its contents are incorporated by reference into this report, while being furnished rather than filed for securities law purposes.
Novo Holdings A/S reports beneficial ownership of 1,872,142 shares of ArriVent BioPharma, representing 4.99% of the company's common stock. The filing states Novo Holdings has sole voting and sole dispositive power over these shares and does not share voting or dispositive power with any other party.
The filer is a Denmark-based investment holding company that manages assets for the Novo Nordisk Foundation and clarifies the Foundation is not deemed to beneficially own the shares held by Novo Holdings. The filing indicates the position is held without intent to change or influence control of ArriVent.
OrbiMed filed Amendment No. 1 to its Schedule 13D regarding ArriVent BioPharma common stock to report a change in beneficial ownership after an increase in shares outstanding. The amendment discloses an aggregate beneficial ownership of 3,027,328 shares, representing approximately 7.5% of the 40,568,944 outstanding shares reported in ArriVent's Quarterly Report. The filing clarifies that OrbiMed Private Investments VIII, LP and OrbiMed Asia Partners IV, L.P. each hold 1,513,664 shares (about 3.7% each) and that OrbiMed Advisors, GP VIII, OAP GP IV and Advisors IV have shared or sole voting and dispositive power over those positions.
The Reporting Persons state the shares were acquired for investment purposes and not to obtain control, and confirm they have no current plans to pursue extraordinary transactions or board changes. The filing also summarizes an Amended and Restated Investors' Rights Agreement that provides demand registration rights (requests for S-1 registrations exceeding $20 million), Form S-3 registration rights (thresholds including $5 million and certain percentage holders) and piggyback registration rights, and notes that director Carl L. Gordon is a board member and may receive equity awards subject to transfer obligations to the OrbiMed entities.
ArriVent BioPharma (AVBP) is shown in this Schedule 13G/A as having substantial stakes held by Suvretta Capital Management, LLC and related parties. Suvretta and Aaron Cowen each report shared beneficial ownership of 3,412,788 shares, representing 9.9% of the company’s common stock, while Averill Master Fund, Ltd. reports 2,969,098 shares or 8.7%. All reported shares are held with shared voting and shared dispositive power; none of the reporting persons claim sole voting or sole dispositive power.
The filing states that the securities are directly owned by advisory clients of Suvretta (with Averill identified separately) and includes a certification that the holdings were not acquired to change or influence control. Exhibits listed include a joint filing agreement and control-person identification.